ERα and ERβ expression and transcriptional activity are differentially regulated by HDAC inhibitors
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
The proliferative action of ERalpha largely accounts for the carcinogenic activity of estrogens. By contrast, recent data show that ERbeta displays tumor-suppressor properties, thus supporting the interest to identify compounds that could increase its activity. Here, we show that histone deacetylase inhibitors (HDI) upregulated ERbeta protein levels, whereas it decreased ERalpha expression. Part of this regulation took place at the mRNA level through a mechanism independent of de novo protein synthesis. In addition, we found that, in various cancer cells, the treatment with different HDI enhanced the ligand-dependent activity of ERbeta more strongly than that of ERalpha. On the other hand, in MDA-MB231 and HeLa cells, the expression of ERs modified the transcriptional response to HDI. The use of deletion mutants of both receptors demonstrated that AF1 domain of the receptors was required. Finally, we show that ERbeta expression led to a dramatic increased in the antiproliferative activity of HDI, which correlated with a modification of the transcription of genes involved in cell cycle control by HDI. Altogether, these data demonstrate that the interference of ERbeta and HDAC on the control of transcription and cell proliferation constitute a promising approach for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HDAC inhibitors (HDACi) have been used to treat late-stage breast cancer, but their effectiveness varies among patients, highlighting the importance of identifying the responders to this treatment [9,10,11,12,13].”
From The Synergistic Effect of Proanthocyanidin and HDAC Inhibitor Inhibit Breast Cancer Cell Growth and Promote Apoptosis (2023) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A simplified system for generating recombinant adenoviruses
He, T.-C., Zhou, S., da Costa, L. T., Yu, J., Kinzler, K. W., & Vogelstein, B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.5.2509 · Cited by 3,206
Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture.
Henderson, B. E., Ross, R. K., & Bernstein, L. (1988) · PubMed · Cited by 846
Formation of the Androgen Receptor Transcription Complex
Shang, Y., Myers, M., & Brown, M. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00471-9 · Cited by 672
Paruthiyil, S., Parmar, H., Kerekatte, V., Cunha, G. R., Firestone, G. L., & Leitman, D. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2446 · Cited by 576
Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.
Roger, P., Sahla, M. E., Mäkelä, S., Gustafsson, J. A., Baldet, P., & Rochefort, H. (2001) · PubMed · Cited by 551
Role of Estrogen Receptor Beta in Estrogen Action
Pettersson, K., & Gustafsson, J.-Å. (2001) · Annual Review of Physiology · doi:10.1146/annurev.physiol.63.1.165 · Cited by 491
Vigushin, D. M., Ali, S., Pace, P., Mirsaidi, N., Ito, K., Adcock, I. M., & Coombes, R. C. (2001) · PubMed · Cited by 447
Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer.
Campbell‐Thompson, M., Lynch, I. J., & Bhardwaj, B. (2001) · PubMed · Cited by 417
Fu, M., Wang, C., Reutens, A. T., Wang, J., Angeletti, R. H., Siconolfi-Baez, L., Ogryzko, V., Avantaggiati, M.-L., & Pestell, R. G. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000660200 · Cited by 409
Research works printed but not linked: 1
- McKenna NJ, O’Malley BW . (2002). Endocrinology 143: 2461–2465. · doi:10.1210/endo.143.7.8892 · Paper page
Cited by
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Wagner, J. M., Hackanson, B., Lübbert, M., & Jung, M. (2010) · Clinical Epigenetics · doi:10.1007/s13148-010-0012-4 · Cited by 338
Cracking the Estrogen Receptor's Posttranslational Code in Breast Tumors
Le Romancer, M., Poulard, C., Cohen, P., Sentis, S., Renoir, J.-M., & Corbo, L. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0016 · Cited by 313
Müller, B. M., Jana, L., Kasajima, A., Lehmann, A., Prinzler, J., Budczies, J., Winzer, K.-J., Dietel, M., Weichert, W., & Denkert, C. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-215 · Cited by 256
Estrogen receptor beta in breast cancer
Haldosén, L.-A., Zhao, C., & Dahlman-Wright, K. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.08.005 · Cited by 189
Estrogen receptor signaling as a target for novel breast cancer therapeutics
Renoir, J.-M., Marsaud, V., & Lazennec, G. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.10.018 · Cited by 193
Self-citationSex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure
Hester, J., Ventetuolo, C., & Lahm, T. (2019) · Comprehensive Physiology · doi:10.1002/cphy.c190011 · Cited by 160
Chemokines: novel targets for breast cancer metastasis
Ali, S., & Lazennec, G. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9073-z · Cited by 180
Self-citationEstrogen signaling: An emanating therapeutic target for breast cancer treatment
Saha, T., Makar, S., Swetha, R., Gutti, G., & Singh, S. K. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.023 · Cited by 134
Potential Role of Estrogen Receptor Beta as a Tumor Suppressor of Epithelial Ovarian Cancer
Bossard, C., Busson, M., Vindrieux, D., Gaudin, F., Machelon, V., Brigitte, M., Jacquard, C., Pillon, A., Balaguer, P., Balabanian, K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044787 · Cited by 117
Self-citationSpecific Activity of Class II Histone Deacetylases in Human Breast Cancer Cells
Duong, V., Bret, C., Altucci, L., Mai, A., Duraffourd, C. C., Loubersac, J., Harmand, P.-O., Bonnet, S., Valente, S., Maudelondé, T., et al. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0299 · Cited by 117
Self-citationDuong, V., Boulle, N., Daujat, S., Chauvet, J., Bonnet, S., Neel, H., & Cavaillès, V. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0967 · Cited by 112
Self-citationSeo, J., Min, S. K., Park, H.-R., Kim, D. H., Kwon, M. J., Kim, L. S., & Ju, Y.-S. (2014) · Journal of Breast Cancer · doi:10.4048/jbc.2014.17.4.323 · Cited by 100
Selective Inhibition of Histone Deacetylase 2 Silences Progesterone Receptor–Mediated Signaling
Biçaku, E., Marchion, D. C., Schmitt, M. L., & Münster, P. N. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2822 · Cited by 87
Experience-facilitated improvements in pup retrieval; evidence for an epigenetic effect
Stolzenberg, D. S., Stevens, J. S., & Rissman, E. F. (2012) · Hormones and Behavior · doi:10.1016/j.yhbeh.2012.05.012 · Cited by 84
Steroid Receptors and Their Role in the Biology and Control of Breast Cancer Growth
Cordera, F., & Jordan, V. C. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.08.020 · Cited by 89
Mostafa, A., Codner, D., Hirasawa, K., Komatsu, Y., Young, M. N., Steimle, V., & Drover, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087377 · Cited by 83
Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases
Božović, A., Mandušić, V., Todorović, L., & Krajnović, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041656 · Cited by 77
Acetylation and nuclear receptor action
Wang, C., Tian, L., Popov, V. M., & Pestell, R. G. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.12.003 · Cited by 74
Targeting triple negative breast cancer with histone deacetylase inhibitors
Fedele, P., Orlando, L., & Cinieri, S. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1386172 · Cited by 75
Picard, N., Charbonneau, C., Sanchez, M., Licznar, A., Busson, M., Lazennec, G., & Tremblay, A. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0281 · Cited by 84
Self-citationChavey, C., Mühlbauer, M., Bossard, C., Freund, A., Durand, S., Jørgensen, C., Jobin, C., & Lazennec, G. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.047332 · Cited by 66
Self-citationTamoxifen Resistance and Epigenetic Modifications in Breast Cancer Cell Lines
Badia, É., Oliva, J., Balaguer, P., & Cavaillès, V. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707782794023 · Cited by 69
Self-citationTargeting Androgen/Estrogen Receptors Crosstalk in Cancer
Karamouzis, M. V., Papavassiliou, K. A., Adamopoulos, C., & Papavassiliou, A. G. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.12.001 · Cited by 63
The Role of Histone Modifications and Variants in Regulating Gene Expression in Breast Cancer
Dalvai, M., & Bystricky, K. (2010) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-010-9167-z · Cited by 62
Fedele, P., Calvani, N., Marino, A., Orlando, L., Schiavone, P., Quaranta, A., & Cinieri, S. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.03.004 · Cited by 55
Dalmau, E., Armengol-Alonso, A., Muñoz-Mateu, M., & Seguí, M. Á. (2014) · The Breast · doi:10.1016/j.breast.2014.09.006 · Cited by 62
Zhu, H., Huang, Q., Xu, H., Niu, L., & Zhou, J. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.08.039 · Cited by 52
Liu, J., Qiu, J., Zhang, Z., Zhou, L., Li, Y., Ding, D., Zhang, Y., Zou, D., Wang, D., Zhou, Q., et al. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00539-y · Cited by 49
Citro, S., Miccolo, C., Meloni, L., & Chiocca, S. (2015) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjv021 · Cited by 48
Loss of tumourigenicity of stably ERβ-transfected MCF-7 breast cancer cells
Behrens, D., Gill, J. H., & Fichtner, I. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.05.012 · Cited by 51
Stolzenberg, D. S., Stevens, J. S., & Rissman, E. F. (2014) · Endocrinology · doi:10.1210/en.2013-1946 · Cited by 40
Bonthuis, P. J., Patteson, J. K., & Rissman, E. F. (2011) · Endocrinology · doi:10.1210/en.2010-1001 · Cited by 37
Linarès, A., Dalenc, F., Balaguer, P., Boulle, N., & Cavaillès, V. (2010) · BioMed Research International · doi:10.1155/2011/856985 · Cited by 36
Self-citationHirao-Suzuki, M., Takeda, S., Okuda, K., Takiguchi, M., & Yoshihara, S. (2018) · Molecular Pharmacology · doi:10.1124/mol.118.114124 · Cited by 37
Ivanova, M. M., Luken, K. H., Zimmer, A. S., Lenzo, F. L., Smith, R. J., Arteel, M. W., Kollenberg, T. J., Mattingly, K. A., & Klinge, C. M. (2011) · The FASEB Journal · doi:10.1096/fj.10-169029 · Cited by 38
Renoir, J. (2012) · Steroids · doi:10.1016/j.steroids.2012.07.019 · Cited by 33
Tu, Z., Li, H., Ma, Y., Tang, B., Tian, J., Akers, W. J., Achilefu, S., & Gu, Y. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-012-1288-9 · Cited by 29
Mayer, H. S., Helton, J., Torres, L. Y., Cortina, I., Brown, W. M., & Stolzenberg, D. S. (2018) · Hormones and Behavior · doi:10.1016/j.yhbeh.2018.02.011 · Cited by 28
Targeting Histone Modifications in Bone and Lung Metastatic Cancers
Edwards, C. M., & Johnson, R. W. (2021) · Current Osteoporosis Reports · doi:10.1007/s11914-021-00670-2 · Cited by 35
Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer
Fedele, P., Orlando, L., Schiavone, P., Calvani, N., Caliolo, C., Quaranta, A., Nacci, A., & Cinieri, S. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.01.001 · Cited by 29
Comparison of the roles of estrogens and androgens in breast cancer and prostate cancer
Liu, W., Zhao, G., Zhang, C., Yang, C., Zeng, X., Li, J., Zhu, K., Zhao, S., Lu, H., Yin, D., et al. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29515 · Cited by 21
Choubey, S. K., Mariadasse, R., Rajendran, S., & Jeyakanthan, J. (2016) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2016.06.082 · Cited by 21
Reproductive experiential regulation of cognitive and emotional resilience
Kinsley, C. H., Bales, K. L., Bardi, M., & Stolzenberg, D. S. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.05.015 · Cited by 21
Fatima, I., Saxena, R., Kharkwal, G., Hussain, M. K., Yadav, N., Hajela, K., Sankhwar, P., & Dwivedi, A. (2013) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.04.005 · Cited by 20
Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance
Pitta, C. A., Papageorgis, P., Charalambous, C., & Constantinou, A. I. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.05.031 · Cited by 19
Wang, T. K., Xu, S., Fan, Y., Wu, J., Wang, Z., Chen, Y., & Zhang, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310476 · Cited by 18
Role of Ghrelin on Estrogen and Progesterone Secretion in the Adult Rat Ovary During Estrous Cycle
Fang, F., Wang, L., Zhang, Y., Li, Y., Su, S., & Zhang, X. (2011) · Systems Biology in Reproductive Medicine · doi:10.3109/19396368.2011.637607 · Cited by 18
Xia, Z., Farhana, L., Correa, R. G., Das, J., Castro, D. J., Yu, J., Oshima, R. G., Reed, J. C., Fontana, J. A., & Dawson, M. I. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200051z · Cited by 18
The silent estrogen receptor--can we make it speak?
Billam, M., Witt, A. E., & Davidson, N. E. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.6.7582 · Cited by 18
Coxsackie and adenovirus receptor is a target and a mediator of estrogen action in breast cancer
Vindrieux, D., Corre, L. L., Hsieh, J., Métivier, R., Escobar, P., Caicedo, A., Brigitte, M., & Lazennec, G. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0230 · Cited by 17
Self-citationSalahuddin, A., Ghanem, H. B., Omran, G. A., & Helmy, M. W. (2022) · Medical Oncology · doi:10.1007/s12032-022-01765-1 · Cited by 17
Li, H., Tu, Z., An, L., Qian, Z., Achilefu, S., & Gu, Y. (2012) · Pharmaceutical Biology · doi:10.3109/13880209.2011.637506 · Cited by 15
Functional Genomic Methods to Study Estrogen Receptor Activity
Gilfillan, S., Fiorito, E., & Hurtado, A. (2012) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-012-9254-4 · Cited by 17
He, T., Liu, J.-X., Duan, C., Li, X.-F., & Zhang, J. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/6653460 · Cited by 15
Vanneste, M., Hanoux, V., Bouakka, M., & Bonnamy, P. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.01.046 · Cited by 14
Sooryanarain, H., Heffron, C. L., Mahsoub, H. M., Hassebroek, A. M., Wang, B., Tian, D., Ahmed, S. A., & Meng, X. (2022) · Journal of Virology · doi:10.1128/jvi.01008-22 · Cited by 15
Guo, J., Zhang, T., Jia, Y., Li, H., Zhao, C., Qiu, J., Zhao, B., Zhao, J., Li, W., & Zhao, T. (2016) · Cell and Tissue Research · doi:10.1007/s00441-015-2347-9 · Cited by 14
The role of p53, bax, bcl2, and 8-OHdG in human acute myocardial infarction
Akbarzadeh, R., Ghaderian, S. M. H., Vakili, H., Panah, A. S. T., Farimani, A. R., Rezaie, G., & Harchegani, A. B. (2010) · Open Life Sciences · doi:10.2478/s11535-010-0030-4 · Cited by 11
Königsberg, M., López‐Díazguerrero, N. E., Rivera-Martinez, L. P., González‐Puertos, V. Y., González-Vieira, R., Gutiérrez‐Ruíz, M. C., & Zentella‐Dehesa, A. (2006) · Comparative Biochemistry and Physiology Part A Molecular & Integrative Physiology · doi:10.1016/j.cbpa.2006.05.005 · Cited by 9
Pitta, C. A., & Constantinou, A. I. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800206-3.00010-0 · Cited by 7
EF24 prevents rotenone‐induced estrogenic status alteration in breast cancer
Roy, D., Kabiraj, P., & Pal, R. (2013) · Cell Biology International · doi:10.1002/cbin.10224 · Cited by 6
Urbinati, G., Marsaud, V., Nicolas, V., Vergnaud, J., & Renoir, J. (2011) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci.2011.005 · Cited by 6
Overexpression of CLDN16 in ovarian cancer is modulated by PI3K and PKC pathways
Paes, M. F., dos Santos, D. Z., Pimenta, T. M., Ribeiro, R. S., Martins, B. D. S., Greco, S. J., de Carvalho, A. A., Bacchi, C. E., Duarte, C., Carvalho, Í., et al. (2023) · Experimental Cell Research · doi:10.1016/j.yexcr.2023.113523 · Cited by 5
N-Myc and STAT Interactor is an Endometriosis Suppressor
Park, Y., Guan, X., & Han, S. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158145 · Cited by 3
Estrogen Receptor Beta (ERβ) May Act as Mediator in Apoptotic Induction of Grape Seed Extract (GSE)
Abroodi, Z., Sajedi, N., Nikbakht, M., & Soleimani, M. (2019) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2019.20.12.3729 · Cited by 2
Role of ERβ in Clinical Breast Cancer
Speirs, V., & Shaaban, A. M. (2008) · Cancer treatment and research · doi:10.1007/978-0-387-09463-2_2 · Cited by 2
Endocrine resistance in advanced breast cancer: current evidence and future directions
Barrios, C. H., Fay, A. P., Debiasi, M., & Werutsky, G. (2012) · Breast Cancer Management · doi:10.2217/bmt.12.48 · Cited by 1
Regulación de la expresión génica de leptina por estradiol en células placentarias
Gambino, Y. P. (2013) · Repositorio Digital Institucional de la Universidad de Buenos Aires (Universidad de Buenos Aires)
Duong, V., Boulle, N., Daujat, S., Neel, H. B., & Cavaill, V. (2008)
Self-citationHdac3 deficiency limits periosteal reaction associated with Western diet feeding in female mice
Vu, E. K., Karkache, I. Y., Pham, A., Koroth, J., & Bradley, E. W. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70081
Liu, J., Qiu, J., Zhang, Z., Zhou, L., Li, Y., Ding, D., Zhang, Y., Zou, D., Wang, D., Zhou, Q., et al. (2021) · Figshare · doi:10.6084/m9.figshare.13632524
Escobar, P. A. (2010) · theses.fr (ABES) · doi:10.70675/6ef77dc7ze8f2z4d7bza761zc1f42658f0a5
Linarès, A. (2011) · theses.fr (ABES) · doi:10.70675/b58d4038z85d2z4a6fza2b6z64e5e5b158c3
Caicedo, A. (2013) · theses.fr (ABES) · doi:10.70675/68880db7z37a4z44c9z9b74z4e3f8d1d6d76
Poulard, C. (2013) · theses.fr (ABES) · doi:10.70675/f9776febz91dez427dzb93bz72501d8a61aa · Cited by 1
BindingDB (2021) · UC San Diego · doi:10.7270/q2w099b9
Metadata
- Authors
- Duong, V, Licznar, A., Margueron, R., Boulle, N., Busson, M., Lacroix, M., Katzenellenbogen, B. S., Cavaillès, V, & Lazennec, G.
- Affiliations
- Inserm (FR)
- Hôpital Arnaud de Villeneuve (FR)
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (FR)
- University of Illinois Urbana-Champaign (US)
- Corresponding author
- Cavaillès, V
- Lazennec, G
- Venue
- Oncogene
- Published
- 2005-09-12
- Volume
- 25
- Issue
- 12
- Pages
- 1799-1806
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- PMC
- PMC2034758
- OpenAlex
- W1590835357
- Cited by
- 75
- References
- 37
- Citations by year
- 2024: 2 · 2023: 2 · 2022: 2 · 2021: 5 · 2020: 1 · 2019: 4 · 2018: 2 · 2017: 2 · 2016: 2 · 2015: 5 · 2014: 4 · 2013: 6 · 2012: 9
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- Ligue Contre le Cancer
- National Institutes of Health
- National Cancer Institute (CA 18119, R01CA018119)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- estrogen receptor alpha, estrogen receptor beta, histone deacetylase inhibitors, transcriptional regulation, mRNA stability, cell proliferation, cell cycle regulation, cancer therapy, MDA-MB-231 cells, HeLa cells
- MeSH terms
- Enzyme Inhibitors, HeLa Cells, Histone Deacetylases, Humans, RNA, Messenger, Transcription, Genetic, Blotting, Western, Polymerase Chain Reaction, Apoptosis, Estrogen Receptor alpha, Estrogen Receptor beta, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.